Back to List View Graph View

CD8-positive T-cell

A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer.

Where the papers sit

10 papers from the last 6 months study CD8-positive T-cell directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 1 human data · 8 preclinical · 1 unclassified

Themes 3 themes · 1 paradigm shift · 1 new direction

  • Mechanisms of T-Cell Immunotherapy

    Cytoskeletal remodeling and matrix stiffening are emerging as barriers to CD8 T-cell immunotherapy. Cofilin1 and LOXL4 affect response through T-cell structure and the tumor matrix, while acetyldigoxin can restore function in lung cancer. AAV delivery is also being examined for rapid, promoter-dependent T-cell activation. The field is moving toward combining immune modulation with strategies that alter tissue barriers and delivery responses.

    3 papers · 30%

  • Tumor T-Cell Exhaustion

    Tumor-reactive CD8 T cells are being defined by divergent fates, from terminal exhaustion to durable memory. LAG3 and TIGIT remain central targets, with a TIGIT-directed IL-12 fusion protein combining checkpoint engagement with NK- and T-cell stimulation. TGR5-dependent dendritic-cell cross-priming adds an antigen-presentation strategy to checkpoint approaches. Treatment is therefore moving beyond single-checkpoint blockade toward coordinated activation and priming.

    3 papers · 30%

  • Others — Interferon-Linked T-Cell Immunity

    Interferon signaling, checkpoint-defined T-cell states and metabolic stress are linked to CD8 T-cell activity across tumors and inflammatory disease. PD-1 and LAG-3 expression can mark clonally expanded cells with favorable gastric-cancer prognosis, while cuproptosis is being explored as a route to overcome immunotherapy resistance. Local interferon delivery may restore antigen presentation and sensitize medulloblastoma to T-cell killing. CX3CR1-positive clonal expansion in anti-NMDA receptor encephalitis broadens the set toward autoimmune neuroinflammation, leaving no single therapeutic direction.

    4 papers · 40%

PARADIGM SHIFT

CD8-positive T cells can create, rather than merely exploit, tumor-cell susceptibility to therapy

The medulloblastoma model studied by the local-interferon delivery paper and the cuproptosis-immunity systems studied by the cuproptosis paper both replace the usual one-way picture in which CD8-positive T cells act only as downstream killers of tumor cells. In medulloblastoma, CD8-derived IFN-γ restores tumor-cell MHC class I and thereby enables T-cell killing; in cuproptosis models, the same cytokine induces tumor-cell FDX1 and increases sensitivity to cuproptosis, while cuproptotic death further stimulates antitumor immunity 42735303Sep 42330950Jun. The resulting change is conceptual as well as therapeutic: CD8-positive T-cell activity is itself a mechanism for remodeling tumor vulnerability and can determine whether otherwise ineffective tumor-directed treatments work.

NEW DIRECTION

CD8-positive T cells are identified as clonally expanded pathogenic effectors in anti-NMDA receptor encephalitis

The anti-NMDA receptor encephalitis study uses single-cell transcriptomic, T-cell-receptor and epitope profiling to assign CD8-positive T cells a disease-driving role outside the set's dominant tumor-immunity and therapeutic-response frameworks. It identifies clonally expanded CX3CR1-expressing CD8-positive T cells in cerebrospinal fluid as disease-associated effectors with predicted GluN1-epitope reactivity, cytotoxic and proinflammatory programs, and interaction with activated B cells, rather than treating them as incidental immune participants 42711907Sep. This redirects attention toward CD8-positive T cells as potential mediators of autoimmune neuroinflammation and therapeutic resistance in anti-NMDA receptor encephalitis.

Papers

The 10 papers from the last 6 months that study CD8-positive T-cell directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Mechanisms of T-Cell Immunotherapy (3)
  1. Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer. Science advances · 11 Sept 2026 PMID 42726857
  2. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  3. CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. JCI insight · 9 Jun 2026 PMID 42262864
Tumor T-Cell Exhaustion (3)
  1. Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells. The Journal of experimental medicine · 18 Aug 2026 PMID 42611047
  2. Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. Signal transduction and targeted therapy · 26 Jul 2026 PMID 42503514
  3. TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine · 16 Jun 2026 PMID 42302794
Others — Interferon-Linked T-Cell Immunity (4)
  1. Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
  2. Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. Proceedings of the National Academy of Sciences of the United States of America · 14 Sept 2026 PMID 42735303
  3. Single-Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti-NMDA Receptor Encephalitis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Sept 2026 PMID 42711907
  4. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950

By study type

Human data, design not indexed (1)
  1. Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
Preclinical: animal, cell and lab studies (8)
  1. Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. Proceedings of the National Academy of Sciences of the United States of America · 14 Sept 2026 PMID 42735303
  2. Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer. Science advances · 11 Sept 2026 PMID 42726857
  3. Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells. The Journal of experimental medicine · 18 Aug 2026 PMID 42611047
  4. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  5. Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. Signal transduction and targeted therapy · 26 Jul 2026 PMID 42503514
  6. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
  7. TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine · 16 Jun 2026 PMID 42302794
  8. CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. JCI insight · 9 Jun 2026 PMID 42262864
Unclassified: not yet indexed with MeSH (1)
  1. Single-Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti-NMDA Receptor Encephalitis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Sept 2026 PMID 42711907